Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma
Source: OncLive, April 2022
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated a statistically significant improvement in progression-free survival (PFS) vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma, according to findings from the phase 2 SWOG S1616 trial (NCT03033576) that were presented during the 2022 AACR Annual Meeting.
At a median follow-up of 28.3 months, the median PFS was 3.0 months (90% CI, 2.8-5.3) with the combination vs 2.7 months (90% CI, 2.5-2.9) with ipilimumab alone (HR, 0.63; 90% CI, 0.41-0.97; P = .037). The estimated 6-month PFS rates were 34% (90% CI, 25%-44%) and 13% (90% CI, 4%-27%), respectively.READ THE ORIGINAL FULL ARTICLE